

**NASDAQ: MYOS**

Last:	\$1.40	Open:	\$1.41
Change:	\$0.00	Prev. Close:	\$1.40
Volume:	39.82k	Last Trade:	10/12 04:00 PM
High:	\$1.42	52-week High:	\$6.98
Low:	\$1.35	52-week Low:	\$1.02
Outstanding:	5,844,372	Market Cap:	\$8.18m

As of 10/12/2017 06:02 PM

[Click here for our current stock quote.](#)



Recent News

Wednesday, September 20, 2017 - 09:03 AM

[MYOS RENS Technology Inc. Appoints Joseph Mannello as Permanent Chief Executive Officer](#)

Wednesday, July 12, 2017 - 06:12 AM

[MYOS RENS to Introduce the Qurr® Line of Muscle Health Products at 35th IDEA World Convention July 19-23, 2017 in Las Vegas](#)

Monday, April 24, 2017 - 06:05 AM

[MYOS RENS Will Be Silver Sponsor at International Conference on Frailty and Sarcopenia Research \(ICFSR\)](#)

Tuesday, April 18, 2017 - 06:05 AM

[MYOS RENS enters into agreement with Kansas State University to study impact of Fortetropin® on reducing muscle loss in dogs after joint surgery](#)

MYOS Corporation

MYOS is an emerging BioTherapeutics and BioNutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases.

MYOS is the owner of Fortetropin™, the first clinically demonstrated natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Fortetropin™ is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards for muscle health.

Investment Highlights

- Consumer-oriented Healthcare Company
- Commercial stage business focused on >\$30B US muscle health market
- Proprietary Fortetropin™ enhances muscle strength and size
- MYOS launched new non-GMO product line called Rē Muscle Health™ (www.remusclehealth.com)
- Utilizing state-of-the-art digital advertising PR & media to generate sales for Rē Muscle Health™
- Product portfolio targeting age management, functional and medical foods, and fitness markets
- Leveraging deep expertise in muscle health and discrete regulatory systems to build biotherapeutics pipeline
- IP strategy to provide commercial protection of Fortetropin™ and related discoveries through 2024 and beyond

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.



- Proven and experienced management team and advisors

Clinical Pipeline

- The Effects of Fortetropin on Anabolic and Catabolic Signaling in Skeletal Muscle (MoA Study) / 100%
- Effects of Fortetropin on Muscle: Clinical effects on lean body mass, fat mass and muscle size; Implications for use and proposed mechanism of action / 100%
- The Effects of Fortetropin on blood chemistry and BMI in healthy adult females / 40%
- Clinical Study on Fortetropin Dose Response / 10%

Management Team

Dr. Robert J. Hariri

Executive Chairman

Dr. Hariri is considered a visionary serial entrepreneur in biomedicine and aerospace. The Chairman, Founder and Chief Executive Officer of one of the world's largest human cellular therapeutics companies, Dr. Hariri has pioneered the use of stem cells and biomaterials to treat a range of life threatening diseases. His activities and experience includes academic neurosurgeon at Cornell, executive, military and defense scientist and surgeon and aviator and aerospace innovator. Dr. Hariri has over 90 issued and pending patents, has authored over 100 published chapters, articles and abstracts and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered TNF (tumor necrosis factor). Dr. Hariri was recipient of the Thomas Alva Edison Award in 2007 and 2011, and has received numerous other honors for his many contributions to biomedicine and aviation.

A jet-rated commercial pilot with many thousands of hours of flight time in over 60 different military and civilian aircraft, Dr. Hariri is a founder and board member of the Rocket Racing League, an extreme aerospace corporation and Jet-A, an FAA certified international heavy jet charter airline. Dr. Hariri serves on numerous Boards of Directors including Myos Corporation and Provista Diagnostics and is a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons; as well as a member of the Scientific Advisory Board for the Archon X PRIZE for Genomics, which is awarded by the X Prize Foundation. Dr. Hariri is also a Trustee of the J. Craig Venter Institute and the Liberty Science Center and has been appointed Commissioner of Cancer Research by New Jersey Governor, Chris Christie. Dr. Hariri received his undergraduate training at Columbia College and Columbia University School of Engineering and Applied Sciences and was awarded his M.D. and Ph.D. degrees from Cornell University Medical College. Dr. Hariri received his surgical training at The New York Hospital-Cornell Medical Center and directed the Aitken Neurosurgery Laboratory and the Center for Trauma Research. We believe Dr. Hariri's training as a scientist, his knowledge and experience with respect to the biomedical and pharmaceutical industries and his extensive research and experience qualifies him to serve on our Scientific Advisory Board.

Dr. Robert Ashton

Chief Medical Officer

Dr. Ashton has over 25 years of experience in medicine, wellness and business. As a board-certified surgeon in both Thoracic Surgery and General Surgery, he had the opportunity to treat a diverse array of disease states, while his main focus was on thoracic oncology and cardiovascular disorders. Dr. Ashton has held various positions including division chief, vice-chairman of a cancer center, member of institutional review boards and quality councils in major academic medical centers. He had the opportunity to perform surgery, lecture and teach nationally and internationally, while publishing over 75 original manuscripts and abstracts. Prior to joining MYOS, Dr. Ashton was Chief Medical Officer of Advanced Practice Strategies, Inc., which focused on lifelong learning for clinicians and risk management solutions for hospitals. Currently, he is a member of the board of directors at Jenrin Discovery and CytImmune Sciences. He was the co-founder of MDLinx, Inc., an online healthcare media company that was acquired by SONY (So-Net M3, a Sony

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.



Communication Network Group Company) in 2006. Dr. Ashton now focuses his efforts on developing solutions to improve the health and longevity of individuals and society. Dr. Ashton holds a Bachelor of Science (BS) in Biology and Philosophy with Honors in both from Muhlenberg College and Medical Degree (MD) from Medical College of Pennsylvania.

Joseph DosSantos

Chief Financial Officer

Mr. DosSantos is an accomplished finance and accounting leader with nearly twenty-five years of senior-level experience in building and managing global finance teams, including over a decade in the pharmaceutical industry.

Mr. DosSantos has an extensive background with solid business acumen and expertise in global public company internal and external financial reporting, accounting and controls, business acquisitions and collaborations, forecasting and budgeting, and management of global shared service functions. Additionally, he has participated in capital raise initiatives for both private and public company throughout his career. Prior to joining MYOS Mr. DosSantos served as Executive Director, Finance Operations, at Actavis plc, a NYSE-listed global specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Previously, he served as Vice President, Corporate Controller, of Alvogen, a multi-national, privately-owned pharmaceutical company focused on developing, manufacturing, and distributing generic, over-the-counter and biosimilar pharmaceutical products. Mr. DosSantos has also served as Senior Director, Assistant Corporate Controller at Celgene Corporation, a NASDAQ-listed global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Additionally he has held positions of increasing responsibilities at Cytex Industries and National Starch & Chemical, two multi-national chemical companies.

Mr. DosSantos is a licensed certified public accountant in New Jersey, graduated from Kean University in 1991 with a BS in Accountancy and holds an MBA in Finance from Seton Hall University.

Company Info

MYOS Corporation
45 Horsehill Rd.
Suite 106
Cedar Knolls, NJ 07927
(973) 509-0444

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.